2022 World Conference on Lung Cancer (ePosters)-EP08.05-001. Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation

EP08.05-001. Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation

Back to course

Pdf Summary

This study evaluated the occurrence of pneumonitis, a lung inflammation, in patients with non-small cell lung cancer who have a specific genetic mutation (EGFR) and are receiving a combination of two treatments: osimertinib, a targeted therapy, and thoracic radiotherapy (TRT). The study aimed to determine if the concurrent use of osimertinib and TRT increased the risk of pneumonitis.<br /><br />The study analyzed data from 41 patients who received both osimertinib and TRT between 2016 and 2020. The primary endpoint of the study was the incidence of symptomatic pneumonitis (Grade 2 according to CTCAE criteria), while the secondary endpoint was the practice patterns of holding or continuing osimertinib during TRT.<br /><br />The results showed that there was no association between concurrent osimertinib and TRT and the incidence of pneumonitis. However, the risk of symptomatic pneumonitis (Grade 2) increased with each additional cycle of osimertinib. Additionally, the risk of pneumonitis (any grade) increased with higher doses of TRT.<br /><br />The study also found a heterogenous practice pattern regarding the administration of osimertinib during TRT, with some patients having the treatment held and others continuing to receive it.<br /><br />The findings indicate that further investigation is needed to understand the toxicities associated with the combination of novel targeted therapies and radiotherapy in the treatment of lung cancer.<br /><br />In summary, this study found that the concurrent use of osimertinib and TRT did not increase the risk of pneumonitis in patients with EGFR-mutated non-small cell lung cancer. However, the risk of symptomatic pneumonitis was higher with each additional cycle of osimertinib, and higher doses of TRT were associated with an increased risk of pneumonitis. The practice patterns of holding or continuing osimertinib during TRT varied among patients. More research is needed to understand the effects of multimodality treatments in the era of novel targeted therapies and immunotherapies.

Asset Subtitle

David Y. Mak

Meta Tag

Speaker David Y. Mak

Topic Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy

Keywords

pneumonitis

lung inflammation

non-small cell lung cancer

EGFR

osimertinib

thoracic radiotherapy

TRT

symptomatic pneumonitis

practice patterns

targeted therapies